Patents Assigned to Boehringer Ingelheim International GmbH
  • Stereoselective process
    Patent number: 10189776
    Abstract: The invention relates to a method for the stereoselective preparation of compounds of formula (IV).
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: January 29, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uwe Joerg Ries, Nizar Haddad, Bo Qu
  • Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists
    Patent number: 10183940
    Abstract: The invention relates to aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amide derivatives of general formula (1), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates processes for manufacture of the compounds according to the invention.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: January 22, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rocco Mazzaferro, Marco Ferrara, Riccardo Giovannini, Iain Lingard
  • Anti-IGF antibodies
    Patent number: 10179810
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: January 15, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Eric Borges, Robert Rauchenberger, Gabriela Wochnik-Veltrup
  • Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
    Patent number: 10160723
    Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: December 25, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
  • Medicaments for the treatment or prevention of fibrotic diseases
    Patent number: 10154990
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Inhaler
    Patent number: 10155094
    Abstract: An inhaler is proposed having an insertable container and a monitoring device for counting uses of the inhaler. The monitoring device is arranged in a detachable housing part or fitted onto a mouthpiece of the inhaler. A supply air current is detected by means of a pressure sensor. A position sensor may further be provided.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Herbert Wachtel, Andree Jung
  • Medical use of pharmaceutical combination or composition
    Patent number: 10155000
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Meinicke, Maximilian Von Eynatten
  • Pyrazolyl-substituted heteroaryls and their use as medicaments
    Patent number: 10155751
    Abstract: The invention relates to new substituted heteroaryls of formula 1 or of formula 1? wherein A is either N or CH, wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl, wherein Y is selected from —O— or —CH2—, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Hoffmann, Georg Dahmann, Christian Gnamm, Daniel Robert Fandrick, John Scott, Clive McCarthy
  • Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
    Patent number: 10155749
    Abstract: The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (TPSA) of at least 145, wherein R1, R2, R3, R4, X, and Z? have one of the meanings as defined in the specification, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Dieter Hamprecht, Joerg Kley
  • INACTIVATION OF PROTEASES
    Publication number: 20180346950
    Abstract: The invention relates to a process for inactivating proteases by repeatedly changing the pH in the cell culture supernatant at the start of the process for the purification of biopharmaceuticals. The pH is adjusted first to 3-5, and then to 7-9.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Alexander JACOBI, Dorothee AMBROSIUS, Philine DOBBERTHIEN, Christian ECKERMANN, Franz NOTHELFER
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10144739
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl
  • Substituted benzamides as RIPK2 inhibitors
    Patent number: 10138241
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Pingrong Liu, Craig Andrew Miller, Maolin Yu, Zhonghua Zhang, Sabine Ruppel, Anil K. Padyana
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 10138229
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Joshua Courtney Horan, Shuang Liang, Can Mao, Wang Mao, Yue Shen, Fariba Soleymanzadeh, Renee M. Zindell
  • Substituted benzamides as RIPK2 inhibitors
    Patent number: 10138222
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1—, R2—, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jianwen Cui, Donghong Amy Gao, Pingrong Liu, Bryan Patrick McKibben, Craig Andrew Miller, Hossein Razavi, Elizabeth Spencer, Sabine Ruppel, Anil K. Padyana
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10138251
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Tobias Wunberg
  • METHODS OF TREATING DISEASES
    Publication number: 20180334501
    Abstract: This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: June 27, 2018
    Publication date: November 22, 2018
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Kirsten Arndt-Schmitz, Alix Berton, Michael Chadham Nivens, Karsten Quast, Marco Schlepuetz, Sudha Visvanathan
  • Aldosterone synthase inhibitors
    Patent number: 10131642
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jörg M. Bentzien, Jennifer Burke, Derek Cogan, Xin Guo, Keith R. Hornberger, John Lord, Kenneth M. Meyers, Zhaoming Xiong, Maolin Yu, Zhonghua Zhang
  • Process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione
    Patent number: 10131618
    Abstract: This invention relates to methods for the synthesis of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Xiangle Jin, Weitong Dong, Yan Fu, Jun Lu, Le Xie, Wei Xu, Jinsong Yang, Qian Zhu
  • Nebulizer
    Patent number: 10124125
    Abstract: A nebulizer includes an insertable container and a securing mechanism for holding the container in the nebulizer such that the container can move back and forth but cannot be separated. The securing mechanism is formed by a metal unitary part. The securing mechanism forms a transportation lock for holding the container unmovable in the housing in a delivery state of the nebulizer. The securing mechanism forms a cage which encompasses the container.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: November 13, 2018
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Alexander Bach, Jens Besseler, Holger Holakovsky, Manuel Daelman, Gilbert Wuttke
  • Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Patent number: 10125101
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are as defined herein, which compounds have valuable pharmacological properties, in particular their ability to bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular type 2 diabetes. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 13, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner, Stefan Peters